TRxADE HEALTH Future Growth
Future criteria checks 0/6
Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für TRxADE HEALTH zu prognostizieren.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Healthcare Services earnings growth | 26.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
TRxADE Health prices of $1.8M stock offering
Oct 05TRxADE Health launches next day delivery services via Trxade prime plus program
Aug 30TRxADE Health proposes public stock offering
Aug 23Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M
Jul 25Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?
Mar 30Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation
Nov 23Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates
Jul 29Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)
Jun 16SpartanNash and Bonum Health join hands to provide telemedicine services
Jun 07Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being
May 22Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00
Apr 28Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook
Apr 01Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?
Feb 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TRxADE HEALTH has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2023 | 9 | -4 | 0 | 0 | N/A |
6/30/2023 | 9 | -4 | 0 | 0 | N/A |
3/31/2023 | 10 | -3 | -2 | -1 | N/A |
12/31/2022 | 11 | -3 | -2 | -2 | N/A |
9/30/2022 | 10 | -3 | -4 | -3 | N/A |
6/30/2022 | 11 | -4 | -4 | -3 | N/A |
3/31/2022 | 10 | -6 | -3 | -3 | N/A |
12/31/2021 | 10 | -5 | -3 | -3 | N/A |
9/30/2021 | 9 | -7 | -3 | -3 | N/A |
6/30/2021 | 13 | -5 | 0 | 0 | N/A |
3/31/2021 | 18 | -3 | -3 | -3 | N/A |
12/31/2020 | 17 | -3 | -2 | -2 | N/A |
9/30/2020 | 17 | -1 | -2 | -2 | N/A |
6/30/2020 | 13 | -1 | -4 | -4 | N/A |
3/31/2020 | 8 | 0 | 0 | 0 | N/A |
12/31/2019 | 7 | 0 | 0 | 0 | N/A |
9/30/2019 | 7 | 0 | 0 | 0 | N/A |
6/30/2019 | 6 | 0 | 0 | 0 | N/A |
3/31/2019 | 4 | 0 | 0 | 0 | N/A |
12/31/2018 | 4 | 0 | 0 | 0 | N/A |
9/30/2018 | 3 | 0 | 0 | 0 | N/A |
6/30/2018 | 3 | 0 | 0 | 0 | N/A |
3/31/2018 | 3 | 0 | 0 | 0 | N/A |
12/31/2017 | 3 | 0 | 0 | 0 | N/A |
9/30/2017 | 3 | 0 | 0 | 0 | N/A |
6/30/2017 | 3 | 0 | N/A | -1 | N/A |
3/31/2017 | 3 | -1 | N/A | -1 | N/A |
12/31/2016 | 2 | -1 | N/A | -1 | N/A |
9/30/2016 | 1 | -1 | N/A | -2 | N/A |
6/30/2016 | 2 | -1 | N/A | -2 | N/A |
3/31/2016 | 3 | 0 | N/A | -2 | N/A |
12/31/2015 | 3 | 0 | N/A | -2 | N/A |
9/30/2015 | 4 | -1 | N/A | -1 | N/A |
6/30/2015 | 3 | -1 | N/A | -1 | N/A |
3/31/2015 | 2 | -2 | N/A | -1 | N/A |
12/31/2014 | 1 | -2 | N/A | -1 | N/A |
9/30/2014 | 1 | -3 | N/A | -1 | N/A |
6/30/2014 | 1 | -3 | N/A | -1 | N/A |
3/31/2014 | 1 | -3 | N/A | -1 | N/A |
12/31/2013 | 1 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von MEDS über der Sparquote liegt (2.3%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von MEDS schneller wachsen werden als der Markt US
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von MEDS in den nächsten 3 Jahren signifikant steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von MEDS schneller wachsen werden als der Markt von US.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von MEDS schneller wachsen werden als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MEDS in 3 Jahren voraussichtlich hoch sein wird